41.77
+0.03(+0.07%)
Currency In USD
| Previous Close | 41.74 |
| Open | 42.5 |
| Day High | 42.75 |
| Day Low | 41.3 |
| 52-Week High | 46.01 |
| 52-Week Low | 14.8 |
| Volume | 235,543 |
| Average Volume | 954,179 |
| Market Cap | 3.13B |
| PE | -20.38 |
| EPS | -2.05 |
| Moving Average 50 Days | 41.84 |
| Moving Average 200 Days | 30.42 |
| Change | 0.03 |
New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer
GlobeNewswire Inc.
Dec 05, 2025 1:30 PM GMT
Cretostimogene demonstrated HG-EFS at 3- 6- and 9-months of 95.7%, 84.6% and 80.4%, respectively, in HR BCG UR Ta/T1 Disease in BOND-003 Cohort PCORE-008 Cohort A Data in HR BCG-Naïve NMIBC demonstrates 88% CR and favorable safety with optimized admi
CG Oncology Announces New Board Member and Board Transition
GlobeNewswire Inc.
Nov 26, 2025 12:00 PM GMT
- Appoints Accomplished Life Sciences Executive Christina Rossi to its Board of Directors - IRVINE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing an
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual Meeting
GlobeNewswire Inc.
Nov 25, 2025 9:05 PM GMT
Two late-breaking podium presentations and three posters continue to demonstrate cretostimogene as a potential backbone therapy for a broad range of NMIBC patientsIRVINE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a